Adial Pharmaceuticals posts bigger-than-expected Q2 net loss, hurt by acquisition charges

Adial Pharmaceuticals

17/08/2026 12:14

Overview
US biopharmaceutical firm's Q2 net loss widened, coming below analyst expectations
Q2 loss per share came below analyst expectations, driven by acquisition-related non-cash charges
Company completed Azora Therapeutics acquisition and closed $32 mln private financing tranche

Outlook
Company expects to file IND for AT177 in first half of 2027
Adial plans to start Phase 1a clinical trial for AT177 in second half of 2027
Company expects existing cash to fund operations into second half of 2027

Result Drivers
ACQUISITION CHARGES - Net loss widened mainly due to a $46.2 mln non-cash charge for acquired in-process research and development from Azora Therapeutics acquisition
MERGER COSTS - General and administrative expenses rose due to merger-related costs and severance expenses
REDUCED R&D ACTIVITY - Research and development expenses declined as company focused on merger discussions

Company press release: ID:nGNX6hY1n7

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Miss
$11.25
$1.03 (4 Analysts)
Q2 Net Loss
Miss
$52 mln
$2.008 mln (3 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Adial Pharmaceuticals Inc is $8.00, about 101% above its August 14 closing price of $3.98

Reuters Recommended Reads
Aug 14 - Quince Therapeutics Q2 net loss widens on acquisition charges
Aug 14 - Cue Biopharma Q2 revenue more than doubles, net loss widens on one-time charges
Aug 14 - LeonaBio Q2 net loss widens on higher R&D spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)